Discover
CTNM
Contineum Therapeutics, Inc.
13.90
1 x 10.19
1 x 22.10
bid
ask
+
0.37
2.73%
1 @ 04:00 PM
13.89 -0.01 (0.07%)
| Ytd | 21.61% | |
| 1y | 146.02% |
13.43
day range
13.95
4.76
52 week range
16.91
| Open | 13.43 | Prev Close | 13.53 | Low | 13.43 | High | 13.95 | Mkt Cap | 519.67M |
| Vol | 169.55K | Avg Vol | 303.07K | EPS | -1.95 | P/E | -7.13 | Forward P/E | -7.68 |
| Beta | 0.70 | Short Ratio | 13.66 | Inst. Own | 72.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 13.51 | 200-d Avg | 12.78 | 1yr Est | 29.25 |
CTNM News
benzinga.com
Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatid
- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial f
benzinga.com
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16
Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-W
benzinga.com
Contineum Therapeutics Q1 EPS $(0.39) Beats $(0.51) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.39) per share which beat the a
benzinga.com
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar
Contineum stock rises after PIPE-791 pain trial shows safety and early efficacy signals, with mixed
benzinga.com
Contineum Therapeutics Announces Its Phase 1b Study Of PIPE-791 Meets Primary Endpoint By Demonstrat
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmace
benzinga.com
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday